To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
LOXO-RET-18036A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours | |
---|---|
Local Project Reference: | 144862 |
Principal Investigator | Dr Sara Stoneham |
Drug Class/ Treatment: | Selpercatinib (LOXO-292) (RET Inhibitor) |
Patient Population: | Paediatric patients ≥ 6 months of age and ≤ 21 years of age at Cycle 1 Day 1 (C1D1)
|
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |